James R. Sowers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James R. Sowers has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
B B Raman
1 shared publicationJeffrey L. Ram
From Departments of Physiology and Internal Medicine, Wayne State University School of Medicine and VA Medical Center, Detroit, Michigan
1 shared publicationJoel Steinberg
Wayne State University School of Medicine
1 shared publicationK Bedford-Rice
1 shared publicationL C Afonso
1 shared publicationLuis C. Afonso
Wayne State University School of Medicine
1 shared publication
Latest Publications
- 1 August 1998
- Vol. 44, 1821-5
Obesity and cardiovascular disease.
Obesity, diabetes mellitus, and hypertension are common, interrelated medical problems in Westernized, industrialized societies. These interrelated medical conditions are associated with an increased risk of cardiovascular disease and are more prevalent in several minority groups, including African-American and Hispanic populations. The associated cardiovascular risks of these problems are more thoroughly addressed in another review in this supplement. Obesity markedly enhances the development of Type 2 diabetes. Moreover, it enhances the cardiovascular risk associated with other risk factors, such as hypertension and dyslipidemia. Weight reduction in association with an aerobic exercise program improves metabolic abnormalities and reduces blood pressure in individuals with diabetes and hypertension.
- 1 August 1998
- Vol. 44, 1821-5
Obesity and cardiovascular disease.
Obesity, diabetes mellitus, and hypertension are common, interrelated medical problems in Westernized, industrialized societies. These interrelated medical conditions are associated with an increased risk of cardiovascular disease and are more prevalent in several minority groups, including African-American and Hispanic populations. The associated cardiovascular risks of these problems are more thoroughly addressed in another review in this supplement. Obesity markedly enhances the development of Type 2 diabetes. Moreover, it enhances the cardiovascular risk associated with other risk factors, such as hypertension and dyslipidemia. Weight reduction in association with an aerobic exercise program improves metabolic abnormalities and reduces blood pressure in individuals with diabetes and hypertension.
- Open Access
- 1 August 1998
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 44 (8) , 1821-1825
Obesity and cardiovascular disease
Obesity, diabetes mellitus, and hypertension are common, interrelated medical problems in Westernized, industrialized societies. These interrelated medical conditions are associated with an increased risk of cardiovascular disease and are more prevalent in several minority groups, including African-American and Hispanic populations. The associated cardiovascular risks of these problems are more thoroughly addressed in another review in this supplement. Obesity markedly enhances the development of Type 2 diabetes. Moreover, it enhances the cardiovascular risk associated with other risk factors, such as hypertension and dyslipidemia. Weight reduction in association with an aerobic exercise program improves metabolic abnormalities and reduces blood pressure in individuals with diabetes and hypertension.
- 1 August 1998
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 44 (8) , 1821-1825
Open AccessObesity and cardiovascular disease
Obesity, diabetes mellitus, and hypertension are common, interrelated medical problems in Westernized, industrialized societies. These interrelated medical conditions are associated with an increased risk of cardiovascular disease and are more prevalent in several minority groups, including African-American and Hispanic populations. The associated cardiovascular risks of these problems are more thoroughly addressed in another review in this supplement. Obesity markedly enhances the development of Type 2 diabetes. Moreover, it enhances the cardiovascular risk associated with other risk factors, such as hypertension and dyslipidemia. Weight reduction in association with an aerobic exercise program improves metabolic abnormalities and reduces blood pressure in individuals with diabetes and hypertension.
- Open Access
- 23 March 1998
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 158 (6) , 617-621
Diabetes Mellitus and Cardiovascular Disease in Women
WHILE coronary heart disease (CHD) has generally been considered a disease affecting men, the World Health Organization in 19901 reported that heart disease is the leading cause of death for women of all ages in the United States. This disease accounts for nearly 30% of all deaths among women.2,3 The incidence of CHD in women rises exponentially with age in industrialized, westernized societies.4 Below the age of 55 years, the incidence of CHD in women is one third that of men; however, this ratio approaches unity at age 75 years. Indeed, more than a quarter of a million women aged 50 through 79 years die of CHD in the United States each year. As discussed in this article, the rising incidence of CHD parallels increases in the incidence of both hypertension and diabetes with increasing age in the United States.4-9 Since, as previously extensively reviewed,8-10 the mortality from CHD and myocardial infarction is significantly worse in women than in men, it is important that we better understand the underlying factors that predispose women both to CHD and associated mortality.11 This article examines those underlying factors with special attention to the important role of diabetes mellitus in promoting CHD and associated mortality in women.
- 23 March 1998
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 158 (6) , 617-621
Open AccessDiabetes Mellitus and Cardiovascular Disease in Women
WHILE coronary heart disease (CHD) has generally been considered a disease affecting men, the World Health Organization in 19901 reported that heart disease is the leading cause of death for women of all ages in the United States. This disease accounts for nearly 30% of all deaths among women.2,3 The incidence of CHD in women rises exponentially with age in industrialized, westernized societies.4 Below the age of 55 years, the incidence of CHD in women is one third that of men; however, this ratio approaches unity at age 75 years. Indeed, more than a quarter of a million women aged 50 through 79 years die of CHD in the United States each year. As discussed in this article, the rising incidence of CHD parallels increases in the incidence of both hypertension and diabetes with increasing age in the United States.4-9 Since, as previously extensively reviewed,8-10 the mortality from CHD and myocardial infarction is significantly worse in women than in men, it is important that we better understand the underlying factors that predispose women both to CHD and associated mortality.11 This article examines those underlying factors with special attention to the important role of diabetes mellitus in promoting CHD and associated mortality in women.
- 1 January 1998
- Published by Wolters Kluwer Health in Hypertension
- Vol. 31 (1) , 289-295
Calcium and Protein Kinase C Mediate High-Glucose-Induced Inhibition of Inducible Nitric Oxide Synthase in Vascular Smooth Muscle Cells
Abnormal vascular smooth muscle (VSMC) proliferation is a key feature in diabetes-associated atherosclerotic disease. Since nitric oxide inhibits VSMC tone, migration, adhesion, and proliferation, we examined the effects of high glucose on IL-1β-induced NO release from VSMCs in culture. Confluent smooth muscle cells, preincubated with either 5 mmol/L (mM) or 20 mmol/L (mM) glucose for 48 hours, were stimulated with IL-1β. Nitrite was measured in the culture medium after 24 hours. IL-1β-induced a 15-fold increase in NO production in normal glucose medium. Glucose (10 to 30 mmol/L (mM)) significantly reduced the response to IL-1β. High glucose (20 mmol/L (mM) inhibited IL-1β-evoked NO production by approximately 50%. IL-1β-stimulated [3H] citrulline-forming activity of the nitric oxide synthase (NOS) was also significantly lower in high-glucose-exposed cells, and this was reflected in diminished cellular levels of NOS protein. To assess the role of protein kinase C (PKC), membrane PKC activity was measured, and glucose (20 mmol/L (mM)) significantly increased it. Immunoblotting of the membranes revealed a glucose-induced increase in the PKC βII isoform. 1,2-Dioctanoyl-glycerol, a PKC activator, mimicked the high-glucose effect on IL-1β-induced NO release, while staurosporine, a PKC inhibitor, reversed it. The role of calcium in the glucose-mediated inhibition of cytokine-induced NO release was determined by treatment with BAPTA, an intracellular chelator of calcium. BAPTA partially reversed the inhibitory effects of glucose. Increasing intracellular calcium by A23187, an ionophore or thapsigargin, an inhibitor of endoplasmic reticulum Ca2+-ATPase, significantly decreased IL-1β-induced NO release and NOS expression. These results indicate that glucose-induced inhibition of IL-1β-stimulated NO release and NOS expression may be mediated by PKC activation and increased intracellular calcium.
- 1 January 1998
- Published by Wolters Kluwer Health in Hypertension
- Vol. 31 (1) , 289-295
Calcium and Protein Kinase C Mediate High-Glucose-Induced Inhibition of Inducible Nitric Oxide Synthase in Vascular Smooth Muscle Cells
Abnormal vascular smooth muscle (VSMC) proliferation is a key feature in diabetes-associated atherosclerotic disease. Since nitric oxide inhibits VSMC tone, migration, adhesion, and proliferation, we examined the effects of high glucose on IL-1β-induced NO release from VSMCs in culture. Confluent smooth muscle cells, preincubated with either 5 mmol/L (mM) or 20 mmol/L (mM) glucose for 48 hours, were stimulated with IL-1β. Nitrite was measured in the culture medium after 24 hours. IL-1β-induced a 15-fold increase in NO production in normal glucose medium. Glucose (10 to 30 mmol/L (mM)) significantly reduced the response to IL-1β. High glucose (20 mmol/L (mM) inhibited IL-1β-evoked NO production by approximately 50%. IL-1β-stimulated [3H] citrulline-forming activity of the nitric oxide synthase (NOS) was also significantly lower in high-glucose-exposed cells, and this was reflected in diminished cellular levels of NOS protein. To assess the role of protein kinase C (PKC), membrane PKC activity was measured, and glucose (20 mmol/L (mM)) significantly increased it. Immunoblotting of the membranes revealed a glucose-induced increase in the PKC βII isoform. 1,2-Dioctanoyl-glycerol, a PKC activator, mimicked the high-glucose effect on IL-1β-induced NO release, while staurosporine, a PKC inhibitor, reversed it. The role of calcium in the glucose-mediated inhibition of cytokine-induced NO release was determined by treatment with BAPTA, an intracellular chelator of calcium. BAPTA partially reversed the inhibitory effects of glucose. Increasing intracellular calcium by A23187, an ionophore or thapsigargin, an inhibitor of endoplasmic reticulum Ca2+-ATPase, significantly decreased IL-1β-induced NO release and NOS expression. These results indicate that glucose-induced inhibition of IL-1β-stimulated NO release and NOS expression may be mediated by PKC activation and increased intracellular calcium.
- 1 January 1998
- Published by Springer Nature
- p. 75-82
Metabolic and Cardiovascular Manifestations of Hypertension in the Elderly
- 1 January 1998
- Published by Springer Nature
- p. 75-82
Metabolic and Cardiovascular Manifestations of Hypertension in the Elderly
- 1 March 1997
- Published by Wolters Kluwer Health in Hypertension
- Vol. 29 (3) , 691-699
Insulin and Insulin-Like Growth Factor in Normal and Pathological Cardiovascular Physiology
- 1 March 1997
- Published by Wolters Kluwer Health in Hypertension
- Vol. 29 (3) , 691-699
Insulin and Insulin-Like Growth Factor in Normal and Pathological Cardiovascular Physiology
- 1 March 1996
- Vol. 10 (3) , 177-80
Effects of antihypertensive therapy on platelet cytosolic calcium responses to low density lipoprotein cholesterol.
This study examines the effects of antihypertensive therapy on platelet cytosolic calcium [Ca2+]i responses to low-density lipoprotein cholesterol (LDL) and vasopressin (AVP) in 15 patients (50-80 years) participating in the Hypertension Optimal Treatment International Study. All patients (diastolic blood pressure (DBP) > or = 100 mm Hg and < or = 115 mm Hg) were treated with the calcium antagonist felodipine (10 mg p.o.) with or without addition of enalapril (up to 20 mg daily as needed) to lower diastolic pressures to < 85 mm Hg. This antihypertensive therapy lowered DBP (104 +/- 0.8 to 78 +/- 1.6 mm Hg, P < 0.0001), but had no effect on basal [Ca2+]i or AVP-stimulated [Ca2+]i responses. Basal platelet [Ca2+]i following antihypertensive therapy (49 +/- 3.4 ng/ml) were not different from those prior to therapy (52 +/- 4.7 ng/ml). Additionally, [Ca2+]i responses to AVP following therapy (554 +/- 74 units) were not different from those prior to treatment (595 +/- 49 units). Following antihypertensive therapy, [Ca2+]i responses to 200 micrograms/ml of LDL were decreased fourfold (P < 0.05). These results suggest that antihypertensive therapy with a calcium channel blocker may potentially impact the atherogenic process by reducing the platelet [Ca2+]i rise, and potentially the aggregatory response, to LDL.
- 1 March 1996
- Vol. 10 (3) , 177-80
Effects of antihypertensive therapy on platelet cytosolic calcium responses to low density lipoprotein cholesterol.
This study examines the effects of antihypertensive therapy on platelet cytosolic calcium [Ca2+]i responses to low-density lipoprotein cholesterol (LDL) and vasopressin (AVP) in 15 patients (50-80 years) participating in the Hypertension Optimal Treatment International Study. All patients (diastolic blood pressure (DBP) > or = 100 mm Hg and < or = 115 mm Hg) were treated with the calcium antagonist felodipine (10 mg p.o.) with or without addition of enalapril (up to 20 mg daily as needed) to lower diastolic pressures to < 85 mm Hg. This antihypertensive therapy lowered DBP (104 +/- 0.8 to 78 +/- 1.6 mm Hg, P < 0.0001), but had no effect on basal [Ca2+]i or AVP-stimulated [Ca2+]i responses. Basal platelet [Ca2+]i following antihypertensive therapy (49 +/- 3.4 ng/ml) were not different from those prior to therapy (52 +/- 4.7 ng/ml). Additionally, [Ca2+]i responses to AVP following therapy (554 +/- 74 units) were not different from those prior to treatment (595 +/- 49 units). Following antihypertensive therapy, [Ca2+]i responses to 200 micrograms/ml of LDL were decreased fourfold (P < 0.05). These results suggest that antihypertensive therapy with a calcium channel blocker may potentially impact the atherogenic process by reducing the platelet [Ca2+]i rise, and potentially the aggregatory response, to LDL.